MeSH D013274 - stomach neoplasms
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Accord Healthcare | Capecitabine | Capecitabine Accord |  | 2012-04-20 |  |  |
| Docetaxel | Docetaxel |  | 2011-06-08 |  |  | |
| Docetaxel | Docetaxel Accord |  | 2012-05-22 |  |  | |
| Fluorouracil | Fluorouracil |  | 2007-04-26 |  |  | |
| Mitomycin | Mitomycin |  | 1998-04-30 |  |  | |
| Trastuzumab | Zercepac |  | 2020-07-27 |  |  | |
| Cisplatin | Cisplatin |  | 2015-08-18 |  |  | |
| Irinotecan | Irinotecan |  | 2008-11-21 |  |  | |
| Methotrexate | Methotrexate |  | 2007-04-30 |  |  | |
| ACIC Pharmaceuticals | Docetaxel | Docetaxel |  | 2024-02-28 |  |  |
| Alembic Pharmaceuticals | Docetaxel | Docetaxel |  | 2023-02-28 |  |  |
| Fluorouracil | Fluorouracil |  | 2023-03-03 |  |  | |
| Allergan | Docetaxel | Docetaxel |  | 2013-04-12 |  |  |
| Irinotecan | Irinotecan |  | 2008-02-27 |  |  | |
| American Regent | Floxuridine | Floxuridine |  | 2017-11-22 |  |  |
| Amgen | Trastuzumab | Kanjinti |  | 2018-05-16 |  |  |
| Amneal Pharmaceuticals | Docetaxel | Docetaxel |  | 2018-01-19 |  |  |
| Methotrexate | Methotrexate |  | 2017-12-22 |  |  | |
| Apotex | Docetaxel | Docetaxel |  | 2012-01-11 |  |  |
| APP Pharmaceuticals | Fluorouracil | Fluorouracil |  | 1986-03-21 |  |  |
| Methotrexate | Methotrexate |  | 1985-10-11 |  |  | |
| Astex Pharmaceuticals | Mitomycin | Mitozytrex |  | 2002-11-14 |  |  |
1
2
3
4
5
6
7
>
Clinical Trials
Historical Success Rate
Phase 1
74%103/139
Phase 2
30%57/192
Phase 3
41%42/103
Approved: 16Overall Success rate: 9%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
4
5
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use